Cagrilintide
Also known as: AM833, NN9838, CagriSema (combination)
Popular For
Weight loss, appetite control, combination therapy
Key Facts: Cagrilintide
- Category
- Weight Loss
- FDA Status
- Not FDA Approved
- Clinical Status
- Phase 3 Trials - Not yet FDA approved
- Administration
- Subcutaneous injection once weekly
- Typical Dose
- 2.4 mg weekly
- Frequency
- Once weekly
- Evidence Level
- Human Trials
- Duration
- Long-term / chronic use expected
Mechanism of Action
Cagrilintide mimics amylin, a hormone co-secreted with insulin from pancreatic beta cells. It activates amylin and calcitonin receptors in the area postrema and nucleus tractus solitarius of the brainstem, enhancing satiety signaling. Unlike GLP-1 agonists, it works through homeostatic and hedonic appetite centers, reducing hunger and promoting earlier meal termination. Also slows gastric emptying to prolong fullness.
Research Summary
REDEFINE 1 Phase 3 trial showed 11.8% weight loss with cagrilintide monotherapy vs 2.3% placebo over 68 weeks. Combined with semaglutide (CagriSema), average weight loss reached 20.4% vs 3.0% placebo. 60% of CagriSema participants achieved ≥20% weight loss, and 23% lost ≥30%. This represents some of the most significant weight loss results seen with any anti-obesity medication.
Dosing Information
Typical Dosingⓘ
Community experience
2.4 mg weekly
1.0-2.4 mg weekly (dose escalation)
Once weekly
Most effective when combined with semaglutide (CagriSema). Works through amylin pathway which is complementary to GLP-1 mechanism. Dose escalation typically used to minimize GI side effects. Not yet commercially available - still in clinical trials.
Research Dosingⓘ
Scientific studies
Doses from clinical trials - not yet approved
Doses from Studies
2.4 mg cagrilintide + 2.4 mg semaglutide weekly
REDEFINE 1 Trial (CagriSema) - Phase 3 - 20.4% weight loss with combination ↗
Duration
Long-term / chronic use expected
Administration
Subcutaneous injection once weekly
Timing & Administration
Best Time to Take
Any consistent time weekly
Once weekly
Food Recommendation
With or without food
Why This Timing?
Once-weekly injection provides sustained amylin receptor activation. Timing is flexible but should be consistent week to week.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Nausea (common, usually transient)
- ●Vomiting
- ●Diarrhea
- ●Constipation
- ●Abdominal pain
- ●Injection site reactions
- ●Decreased appetite
- ●Headache
- ●Dyspepsia
- ●GI events affected 79.6% in CagriSema trials (mostly mild-moderate)
- ●Limited long-term safety data - still in trials
References
Related Peptides
Peptides commonly compared with Cagrilintide or used in similar applications.
Semaglutide
FDAA GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.
Weight LossLiraglutide
FDAAn FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.
Weight LossRetatrutide
Clinical TrialsA triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.
Weight LossSurvodutide
Clinical TrialsA dual GLP-1/glucagon receptor agonist in development for obesity and MASH. Has FDA Breakthrough Therapy Designation for MASH with fibrosis.
Weight LossTirzepatide
FDAA dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.
Weight LossOrforglipron
Clinical TrialsAn oral non-peptide GLP-1 receptor agonist. NDA under FDA review with decision expected April 10, 2026. If approved, will compete directly with oral Wegovy.
Weight LossLooking for a trusted vendor?
Pro members get access to verified vendors with quality standards & exclusive discount codes.
Want updates on Cagrilintide research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.